But deal with Samsung prevents US launch until mid-2023
AbbVie hopes risankizumab will rebuild sales after Humira patent expires
Partnership will use novel approach to treating Alzheimer’s.
No-one can launch biosimilars until patent expires next year
First use for Imbruvica outside blood cancer.
Decision paves way for cheaper competitor in autumn 2018.
Body unconvinced by clinical data for Venclyxto .